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Background: The aim of this study was to evaluate the actions of coenzyme Q10 (CoQ10) on rats with a
cholesterol-rich diet (HD) and high doses of atorvastatin (ATV, 0.2, 0.56 or 1.42 mg/day).
Methods: Two experiments were done, the first one without coenzyme Q10 supplementation. On the second
experiment all groups received coenzyme Q10 0.57 mg/day as supplement. After a 6-week treatment animals were
sacrificed, blood and liver were analyzed and liver mitochondria were isolated and its oxygen consumption was
evaluated in state 3 (phosphorylating state) and state 4 (resting state) in order to calculate the respiratory control
(RC).
Results: HD increased serum and hepatic cholesterol levels in rats with or without CoQ10. ATV reduced these
values but CoQ10 improved even more serum and liver cholesterol. Triacylglycerols (TAG) were also lower in blood
and liver of rats with ATV + CoQ10. HDL-C decreased in HD rats. Treatment with ATV maintained HDL-C levels.
However, these values were lower in HD + CoQ10 compared to control diet (CD) + CoQ10. RC was lessened in liver
mitochondria of HD. The administration of ATV increased RC. All groups supplemented with CoQ10 showed an
increment in RC. In conclusion, the combined administration of ATV and CoQ10 improved biochemical parameters,
liver function and mitochondrial respiration in hypercholesterolemic rats.
Conclusions: Our results suggest a potential beneficial effect of CoQ10 supplementation in hypercholesterolemic
rats that also receive atorvastatin. This beneficial effect of CoQ10 must be combined with statin treatment in patient
with high levels of cholesterol.
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Hypercholesterolemia is considered a risk factor for ath-
erosclerosis and cardiovascular disease. The World
Health Organization expectancy for 2020 is a death rate
of 71% due to ischemic cardiomyopathy [1,2]. According
to the 2012 National Health Survey [3], the prevalence
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article, unless otherwise stated.population. As it is well known, statins constitute the
current therapeutic tool for hyperlipidemia. Atorvastatin
is widely used by clinicians due to its competitive action
on HMG-CoA reductase that results in a decrement of
plasma total cholesterol, low density lipoprotein choles-
terol (LDL-C) and very low density lipoprotein choles-
terol (VLDL-C). It also reduces apolipoprotein B and the
triacylglycerol levels [4]. The hypocholesterolemic action
of statins is well known in human beings and in animal
models. Statins also produce lower levels of plasma chol-
esterol and triacylglycerol, and higher levels of high
density lipoprotein cholesterol (HDL-C) [5]. Statins areCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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able effects such as myositis, rabdomyolysis and liver dam-
age, but their beneficial actions exceed their collateral
effects and so they continue being the first choice for the
prevention of coronary cardiovascular disease [6].
Mevalonate is a precursor of endogenous cholesterol
and other metabolites like ubiquinone, dolichol and other
isoprenoids [7]. Ubiquinone is also known as coenzyme
Q10 (CoQ10), it belongs to a family of compounds that
share a common structure, the benzoquinone ring, and
differ in their isoprenoid lateral chain length; CoQ10 is
a redox component of the mitochondrial respiratory
chain that synthesizes ATP. The reduced form of CoQ10
(ubiquinol) is a powerful lipophilic antioxidant that partic-
ipates in tocopherol and ascorbate recycling as antioxi-
dants [8]. Other reports suggest that statins reduce CoQ10
biosynthesis in the liver. This reduced content could di-
minish oxygen consumption by the mitochondria and
therefore affect the respiratory control. The aim of this
study was to evaluate the role of CoQ10 on metabolic pa-
rameters, liver function and mitochondrial respiration in
rats with high doses of atorvastatin and a cholesterol-rich
diet, a condition which is severely harmful [9] in rodents.
It was employed a ATV1 (0.2 mg/day) dose in rats (200 g
body weight) because it is equivalent to a ATV dose of
60 mg/day in a human being (60 Kg body weight). ATV2
(0.56 mg/day) and ATV3 (1.42 mg/day) correspond to 2.8
and 7 fold higher doses.
Results
Body weight gain and liver weight as a percentage of
body weight
The HD rats showed a higher body weight gain com-
pared to CD rats (p < 0.05), however, there were not sig-
nificant differences in groups HD + ATV1, 2, 3 compared
with HD without CoQ10. HD + ATV1 + CoQ10 showed
less weight gain (77 ± 28 g) with respect to HD + CoQ10Table 1 Weight gain and liver percentage relative to body we
with or without coenzyme Q10 supplementation
CD CD + ATV2
(0.56 /day)
HD
Body weight gain (g)
Without CoQ10 114 ± 20 126 ± 23 140
With CoQ10 95 ± 7
1 102 ± 361 117
Liver percentage
Relative to body weight (%)
Without CoQ10 2.9 ± 0.2 2.7 ± 0.1
a 4.7
With CoQ10 2.38 ± 0.1
1 3.2 ± 0.1a, 1 3.9
CD, control diet; CD + ATV2, CD + atorvastatin 0.56 mg/day; HD, hypercholesterolem
day, Coenzyme Q10, 0.57 mg/day; Data are expressed as mean ± S.E.M.; n = 8. One-
ATV2, HD + ATV3) accompanied by the Student-Newman-Keuls test and differences
vs With CoQ10) (p < 0.05).
aStatistically different from CD (p < 0.05); bstatistically dif
same group without CoQ10.(p < 0.05) (Table 1). A similar pattern was observed be-
tween HD +ATV3 + CoQ10 and HD + CoQ10 (p < 0.05).
Moreover, there was an important diminution of body
weight gain in all groups that received CoQ10 supple-
mentation in comparison with the same groups without
CoQ10 (p < 0.05). On the other hand, the liver percent-
age relative to body weight showed a significant decre-
ment in CD +ATV2 (2.7 ± 0.1%) compared to CD (2.9 ±
0.2%), and a significantly increment in HD (4.7 ± 1.3%)
also in comparison with CD (p < 0.05). Besides, HD +
ATV2 + CoQ10 (3.08 ± 0.13%) and HD +ATV3 + CoQ10
(3.2 ± 0.18%) showed a significant decrement relative to
HD + CoQ10 (3.9 ± 1.1%). The weight gain and the liver
percentage relative to body weight were significantly dif-
ferent between the respective groups with and without
supplementation of CoQ10 in their diet.
Biochemical parameters
The administration of a cholesterol-rich diet produced el-
evated levels of plasma cholesterol in rats with or without
CoQ10 supplementation (249.3 ± 9.0 mg/dL, and 241.5 ±
26.4 mg/dL, respectively) compared with CD (72.2 ±
2.49 mg/dL) and with CD +ATV2 (77.6 ± 3.6 mg/dL); on
the other hand, the supplementation with CoQ10 pro-
duced significant lower values of serum cholesterol in
HD+ATV1, 2, 3 + CoQ10 compared with the same groups
without CoQ10 (p < 0.05) (Figure 1A, B).
Triacylglycerol concentration in serum increased in
HD (77.5 ± 12.5 mg/dL) in comparison with CD (58.6 ±
7.4 mg/dL). HD + ATV1, 2, 3 did not diminish the TAG
levels in comparison with HD, however, in HD +ATV3,
TAG levels were higher (102 ± 16 mg/dL) in comparison
with HD (77.5 ± 12.5 mg/dL). All TAG values were minor
when CoQ10 was added as a supplement (Figure 1C, D)
(p < 0.05).
HDL-C in serum showed a significant decrease in HD
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Figure 1 Effect of a cholesterol-rich diet and atorvastatin given to rats with and without coenzyme Q10 supplementation on
biochemical parameters. Each bar is the mean ± S.E.M. of eight animals. *P < 0.05. Statistical analysis was done by One-way analysis of variance
(ANOVA), followed by the Student-Newman–Keuls test and differences between the groups were determined by the Student's t test (Without
CoQ10 vs With CoQ10).
aStatistically different from CD; bstatistically different from HD; 1statistically different from the same group without CoQ10
(p < 0.05). A, C, E, G without CoQ10; B, D, F, H with Q10. HDL-C (High density lipoprotein-Cholesterol).
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HDL-C levels similar to those of CD group, but lower to
those of CD + CoQ10 (36.82 ± 2.7 mg/dL). Groups CD +
CoQ10, HD + CoQ10 and CD +ATV2 + CoQ10 showed
higher values (36.8 ± 2.7 mg/dL, 28.7 ± 3.2 mg/dL, 34.2 ±
2.1 mg/dL, respectively) than CD without CoQ10 (26.0 ±
2.6 mg/dL). However, HDL-C levels were lower in HD+
ATV1, 2, 3, + CoQ10 (20.2 ± 1.5, 18.6 ± 0.6, 21.8 ± 1.4 mg/dL,
respectively) than in CD + CoQ10 (36.82 ± 2.7 mg/dL)
(Figure 1E, F).
Serum glucose levels significantly increased in HD and
HD+CoQ10 (110.2 ± 1.2 mg/dL and 99.6 ± 0.7 mg/dL, re-
spectively) in comparison with CD and CD+CoQ10 (88.8 ±
4.9 mg/dL; 53.4 ± 12.9, respectively). The treatment with
HD+ATV1 decreased glucose level. However, it was ob-
tained a significant diminution in groups CD, CD +ATV2,
HD and HD+ATV1 treated with CoQ10 supplementation
(Figure 1G, H) in comparison with HD not supplemented.
HD administration induced a slight increase in serum
activity of ALT and AST (84.8 ± 7.9 and 223.6 ±
14.27 IU/L, respectively) in comparison with CD (67.1 ±
9.19 and 165.2 ± 9.7 IU/L, respectively). ATV administra-
tion produced a significant decrease in ALT activity
in HD + ATV2 (60.9 ± 2.5 IU/L) and HD +ATV3 (57.1 ±
5.1 IU/L) in comparison with HD (84.8 ± 7.9 IU/L)
(p <0, 05). CoQ10 supplementation decreased ALT activ-
ity in all groups with cholesterol-rich diet and ATV
(Table 2). On the other hand, serum AST activity in-
creased in CD +ATV2 (209.2 ± 10.8 IU/L) compared
with CD (165.2 ± 9.7 IU/L) and increased in HD +ATV1Table 2 Effect of a cholesterol-rich diet and atorvastatin with
transaminases
CD CD + ATV2 HD
(0.56 mg/day)
ALT
Without CoQ10 67.1 ± 9.19 56.32 ± 0.8
a 84.8 ± 7.9a
With CoQ10 49.05 ± 5.58 48.33 ± 3.86
1 102.6 ± 9.9
AST
Without CoQ10 165.2 ± 9.7 209.2 ± 10.83
a 223.6 ± 14
With CoQ10 227.8 ± 1.98 164.0 ± 1.90
a,1 313.3 ± 4.8
CD, control diet; CD + ATV2, CD + atorvastatin 0.56 mg/day; HD, hypercholesterolemic
Coenzyme Q10, 0.57 mg/day; Data are expressed as mean ± S.E.M.; n = 8. One-w
HD + ATV2, HD + ATV3) accompanied by the Student-Newman-Keuls test and d
(Without CoQ10 vs With CoQ10) (p < 0.05). aStatistically different from either CD or CD
1statistically different from the same group without CoQ10.(273.7 ± 6.98 IU/L) in comparison with HD (223.6 ±
14.27 IU/L) (p <0, 05).
Cholesterol and triacylglycerols from the liver
The administration of a cholesterol-rich diet produced a
significant increase in hepatic cholesterol in HD (12.43 ±
2.84 mg/g) and HD+CoQ10 (6.42 ± 0.86 mg/g) compared
with CD (2.71 ± 0.86 mg/g) or CD+CoQ10 (2.30 ±
0.75 mg/g). ATV administration in HD+ATV1,2,3 de-
creased cholesterol levels in comparison with HD and a
more significant response was obtained when CoQ10 was
supplemented.
Liver triacylglycerol levels were also increased in HD
(10.66 ± 0.33 mg/g) and HD + CoQ10 (10.7 ± 0.32 mg/g)
in comparison with CD (5.58 ± 0.88 mg/g) and CD +
CoQ10 (4.30 ± 0.55 mg/g). On the other hand, HD +
ATV1, 2, 3 diminished TAG levels when compared with
HD, but only with the highest dose the difference was
significant. All the groups HD + ATV with CoQ10 sup-
plementation showed lower values in hepatic TAG levels
than those observed in HD + CoQ10 group (Table 3).
Respiratory control
The respiratory control (RC) was lessened in the liver
mitochondria of HD rats (2.02 ± 0.5) in comparison with
CD (2.98 ± 0.06). The treatment of ATV1 or ATV3 to
HD rats induced a significant increase in oxygen con-
sumption (2.93 ± 0.3 and 2.38 ± 0.35, respectively) in
comparison to HD (2.02 ± 0.5). However, HD + ATV2
showed a lower RC (1.85 ± 0.15) in comparison to HDor without coenzyme Q10 supplementation on
HD+ ATV1 HD + ATV2 HD + ATV3
(0.2 mg/day) (0.56 mg/day) (1.42 mg/day)
128.0 ± 8.9b 60.9 ± 2.5b 57.10 ± 5.11b
1 94.10 ± 18.40 44.15 ± 6.45b,1 56.8 ± 0.75b
.27a 273.7 ± 6.98b 224.6 ± 8.8 196.0 ± 7.31b
7a,1 239.9 ± 9.05b,1 261.4 ± 11.20b,1 247.5 ± 15.45b,1
diet; HD + ATV1, 0.2 mg/day; HD + ATV2 0.56 mg/day; HD + ATV3 1.42 mg/day,
ay analysis of variance (ANOVA) (groups CD, CD + ATV2, HD, HD + ATV1,
ifferences between the groups were determined by the Student's t test
+ CoQ10 (p < 0.05);
bstatistically different from either HD or HD + CoQ10 (p < 0.05);
Table 3 Effect of CoQ10 supplementation on liver cholesterol and triacylglycerols of rats with a cholesterol-rich diet
and atorvastatin
CD CD + ATV2 HD HD + ATV1 HD + ATV2 HD + ATV3
(0.56 mg/day) (0.2 mg/day) (0.56 mg/day) (1.42 mg/day)
TC
Without CoQ10 2.71 ± 0.86 2.77 ± 0.33 12.43 ± 2.84
a 7.80 ± 1.73b 8.71 ± 0.62b 7.38 ± 1.15b
With CoQ10 2.30 ± 0.75 1.87 ± 0.34
a,1 6.42 ± 0.86a,1 2.42 ± 0.47b,1 2.25 ± 0.46b,1 3.30 ± 0.75b,1
TAG
Without CoQ10 5.58 ± 0.88 7.53 ± 0.45
a 10.66 ± 0.33a 9.73 ± 1.95 9.70 ± 1.50 6.31 ± 2.23b
With CoQ10 4.30 ± 0.55
1 6.24 ± 1.16a,1 10.70 ± 0.32a 3.73 ± 0.60b,1 2.81 ± 0.11b, 1 6.47 ± 0.20b
CD, control diet; CD + ATV2, CD + atorvastatin 0.56 mg/day; HD, hypercholesterolemic diet; HD + ATV1, 0.2 mg/day; HD + ATV2 0.56 mg/day; HD + ATV3 1.42 mg/day,
Coenzyme Q10, 0.57 mg/day; Data are expressed as mean ± S.E.M.; n = 8. One-way analysis of variance (ANOVA) (groups CD, CD + ATV2, HD, HD + ATV1, HD + ATV2,
HD + ATV3) accompanied by the Student-Newman-Keuls test and differences between the groups were determined by the Student's t test (Without CoQ10 vs With
CoQ10) (p < 0.05).
aStatistically different from either CD or CD + CoQ10 (p < 0.05);
bstatistically different from either HD or HD + CoQ10 (p < 0.05);
1statistically different
from the same group without CoQ10.
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ment in RC when they were supplemented with CoQ10
(p < 0.05) in comparison with the same groups without
CoQ10 supplementation (Table 4).
Discussion
HD administered to rats induced an increment in serum
cholesterol and triacylglycerols (Figure 1A). These re-
sults are consistent with previous studies [9,10]. As ex-
pected, when ATV was administered, cholesterol and
triacylglycerols showed a dose dependent decrement
(p < 0.05). Supplementation with CoQ10 increased the
effects of ATV on cholesterol levels. Rats with HD showed
a slight increased concentration of serum triacylglycerols.
The administration of ATV did not reduce these TAG
levels, however, all values were minor when CoQ10 was
supplemented (Figure 1C, D).
In our study it was observed a significant diminution
of serum cholesterol in rats that received ATV + CoQ10
in comparison with those groups that did not receive
CoQ10. These results support a better hypolipidemic ef-
fect of ATV in the presence of CoQ10. This improve-
ment in the effect of ATV by CoQ10 has already been
reported in Guinea pigs [10,11].
HDL-C showed a significant decrease in the HD
group. The administration of ATV to HD rats did not
increase HDL-C values but kept them similar to thoseTable 4 Effect of a cholesterol-rich diet and atorvastatin with
mitochondrial respiratory control index
Respiratory
control
CD CD + ATV2 HD
(0.56 mg/day)
Without CoQ10 2.98 ± 0.06 2.25 ± 0.25
a 2.02 ± 0.
With CoQ10 3.20 ± 0.15
1 4.69 ± 0.27a,1 3.68 ± 0.
CD, control diet; CD + ATV2, CD + atorvastatin 0.56 mg/day; HD, hypercholesterolemic
Coenzyme Q10, 0.57 mg/day; Data are expressed as mean ± S.E.M.; n = 8. One-way ana
HD + ATV3) accompanied by the Student-Newman-Keuls test and differences between
CoQ10) (p < 0.05).
aStatistically different from either CD or CD + CoQ10 (p < 0.05);
bstati
from the same group without CoQ10.observed in CD group. However, HDL-C values were
higher in groups CD + CoQ10, HD + CoQ10 and CD +
ATV2 + CoQ10 compared to CD without CoQ10 supple-
mentation (Figure 1E, F). These results confirm the
beneficial effect of ATV on HDL-C levels and even the
more beneficial effect of CoQ10 supplementation on at
least in groups CD + CoQ10, HD + CoQ10 and CD +
ATV2 + CoQ10.
It is well known that statins inhibit cholesterol biosyn-
thesis in the liver, decrease the intracellular cholesterol
content, augment low density lipoprotein-receptor
(LDL-R) synthesis as well as the cholesterol uptake by
the liver, and diminish serum total cholesterol concen-
tration [12]. In addition, statins increment HDL-C levels
throughout an increase of apoprotein A synthesis in the
liver [13] and a reduced activity of cholesterol ester
transfer protein (CETP).
Mabuchi et al. [14] reported that co-administration of
ATV-CoQ10, favored a significant increase of HDL-C in
hypercholesterolemic patients. Singh et al. [15] observed
an important increment of HDL-C in patients that re-
ceived CoQ10. However, it has been reported no increase
in HDL-C in patients that received simvastatin and
CoQ10. Nevertheless, it is not clear how is that synergis-
tic effect of CoQ10 on ATV action. It is well known that
CoQ10 and cholesterol are synthesized by the same path-
way and that high ATV doses produce a significantor without coenzyme Q10 supplementation on the liver
HD + ATV1 HD + ATV2 HD + ATV3
(0.2 mg/day) (0.56 g/day) (1.42 mg/day)
51a 2.93 ± 0.27b 1.85 ± 0.15 2.38 ± 0.35
21a,1 2.72 ± 0.40b 3.55 ± 0.021 3.13 ± 0.221
diet; HD + ATV1, 0.2 mg/day; HD + ATV2 0.56 mg/day; HD + ATV3 1.42 mg/day,
lysis of variance (ANOVA) (groups CD, CD + ATV2, HD, HD + ATV1, HD + ATV2,
the groups were determined by the Student's t test (Without CoQ10 vs With
stically different from either HD or HD + CoQ10 (p < 0.05);
1statistically different
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decrement in serum CoQ10 is related direct or indir-
ectly to the potential liver harm produced by the statin
treatment [16]. On the other hand, CoQ10 administra-
tion may inhibit the expression of the apo A-I recep-
tor, increasing apoprotein A-I and increasing HDL-C
levels [15].
Our results show that rats that received atorvastatin
(0.2 mg/day) and CoQ10 had lower levels of serum glucose
than the same group without CoQ10 (Figure 1G, H). In
addition, CoQ10 regulates glucose levels throughout a
diminution of oxidative stress [17]. On the other hand,
other reports have shown that ATV lowers serum chol-
esterol, increases glucose blood levels and raises insulin
resistance [18]. These data altogether suggest that co-
administration of CoQ10 and ATV improves glucose
metabolism in the hypercholesterolemic state.
Some reports indicate that CoQ10 administration im-
proves pancreatic beta cells function, increases insulin
sensitivity and preserves the mitochondrial function in
the pancreas [19]. Moreover, CoQ10 diminishes lipoper-
oxidation and raises glucose uptake. These results sug-
gest that CoQ10 improves glucose metabolism in
hypercholesterolemia under atorvastatin treatment.
It was also observed in ATV-treated rats an increment
in ALT and AST serum activity. Previous studies have
also shown an increase in serum aminotransferases
(ALT y AST) in rats that received HD and ATV [20,21];
these results were related to liver damage. In accordance
with these results, other animal models with hypercalo-
ric diet are predisposed to hyperlipidemia and liver stea-
tosis [21,22]. On the other hand, a study employing
ATV in rats did not show change in the activity of
serum aminotransferases [10].
The high serum aminotransferases levels in rats with
cholesterol-rich diet are related to liver damage. This
harm is due to membrane damage in hepatocytes which
produces a lessened antioxidant and detoxification cap-
acity of the liver [21]. Other studies have reported higher
activity of transaminases produced by statin administra-
tion to rats [21,22]. On the contrary, our study showed a
slight decrement of AST and ALT activity in ATV-
CoQ10, treated animals compared with those that re-
ceived only ATV. Also, Mabuchi et al. [14] observed a
diminution of AST and ALT in patients treated with
ATV and CoQ10. Moreover, Abbas and Sakr [23] re-
ported a diminution of AST and ALT activity in Guinea
pigs that received simvastatin-CoQ10, comparing with
animals that only received simvastatin. All these results
together may assign a protector effect of CoQ10 on the
hepatocytes of rats fed a cholesterol-rich diet.
In our study, it was observed that ATV lessened chol-
esterol and triacylglycerol concentration in the liver in a
dose-dependent manner in hypercholesterolemic rats.Several reports suggest that this increment induced by
HD contributes to the liver steatosis, as well as the diet-
ary fatty acids and cholesterol promote the lipid accu-
mulation in the hepatocytes. These cells have receptors
for the transcription factor PPAR-α, allowing fatty acid
oxidation in mitochondria, microsomes and peroxisomes
[24]. As a result, fatty acids oxidation products (hydro-
gen peroxide, oxygen superoxide and lipid peroxides)
are produced and induce lipid peroxidation and oxida-
tive stress [25].
Several studies have shown that a cholesterol-rich diet
given to rats produce a fatty liver, hypertrophy of the
liver and macroscopic alterations [25,26] as a conse-
quence of hepatocyte cholesterol saturation; the novo
cholesterol synthesis lowers and consequently it is pro-
duced a diminished uptake of LDL by its receptors.
Results from other studies show a lower activity of HMG-
CoA reductase and lower expression of LDL receptors in
the liver from rats fed a high fat diet [27]. Our study
showed a significant decrease of cholesterol and triacyl-
glycerol levels in the liver of animals treated with ATV
and CoQ10, compared with those rats that only received
ATV. These results are in coincidence with other reports
[11] that suggest CoQ10 improves the hypolipemiant ac-
tion of statins. As we already mentioned it is not currently
known the mechanism by which CoQ10 increases statins
action. Some studies suggest CoQ10 influences the nega-
tive feedback of hepatic cholesterol. Moreover, cholesterol
metabolism in the liver is mediated by lanosterol 14α
demethylase (CYP51) throughout the sterol regulatory
binding proteins (SREBPs) [28,29]. Previous reports study-
ing the effect of the reduced form of CoQ10 on the liver
cholesterol metabolism, showed an antagonistic action on
the ligand binding to X receptor (LXR) [30]. Liver LXRs
induce SREBP-1c, a transcription factor that controls the
expression of several genes involved in cholesterol biosyn-
thesis and its reverse transport. On the other hand, the
amount of dietary cholesterol to be absorbed at the intes-
tine is controlled by a transporter family (ABC), localized
at the enterocyte membrane. These proteins pour out
cholesterol from the enterocytes to the intestine lumen.
The hydroxyl group of the reduced form of CoQ10 is im-
portant for this antagonistic action on ABC transporter
genes throughout the LXR ligand [31]. This mechanism
may explain the cholesterol diminution in serum and liver
observed in all animals that received ATV and CoQ10 in
our study.
It is generally accepted that a cholesterol-rich diet pro-
duces structural mitochondrial alteration in the liver and
higher production of reactive oxygen species (ROS) with
hepatocellular damage [31,32]. Electron microscope
studies in rats with non-alcoholic fatty liver, show scarce
mitochondria, higher in size, deformed, hypodense, with
paracrystaline inclusions, hepatosteatosis and altered
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lower respiratory control. Other authors suggest that a
high-lipid diet induce deterioration of complex I (NAD:
ubiquinone oxidoreductase) and II (succinate dehydro-
genase) of the mitochondrial chain [10]. Other reports
suggest that statins like pravastatin lessen the mitochon-
drial respiratory control affecting complex I and IV
(cytochrome c oxidase) in skeletal muscle [33,34]. In
addition, simvastatin induces myotube atrophy and cell
loss associated with impaired ADP-stimulated maximal
mitochondrial respiratory capacity, mitochondrial oxida-
tive stress [35]. It is known that ATV reduces the
cholesterol-phospholipid ratio in cellular membrane,
raising its fluidity and the activity of ATPase Na+/K+
[36]. All these modifications in cellular membrane affect
the activity of participating enzymes of the mitochon-
drial electron transport chain with probable alteration of
its bioenergetic function. Our results support that the
mitochondrial respiration diminution observed in ani-
mals treated with ATV can be attributed to lower levels
of CoQ10.
The mitochondrial respiratory chain and particularly
complex I and complex III (ubiquinone:cytochrome c
oxidoreductase) are able to produce an anion superoxide
from oxygen. In hepatocytes from normal rats this is a
tenuous production that doesn’t interfere with the re-
spiratory chain activity, but is functioning as a mito-
chondrial protective antioxidant system. On the other
hand, CoQ10 is an invaluable component of the mito-
chondrial respiratory chain [36,37] and a diminution in
its availability affects for sure the energetic metabolism.
It is known that the administration of CoQ10 and simva-
statin increased the activity of complex I in cardiomyo-
cytes but decreased with simvastatin alone. On the other
hand, there are evidences suggesting that the significant
decrease in ATP concentration in simvastatin-treated
rats was due to CoQ10 deficiency [38]. Our results show
a higher mitochondrial RC in all groups that received
ATV and CoQ10. On the same way, Kimura et al. [39]
communicated the increase in muscle fibers contraction
in rats that received CoQ10 due to improvement of cell
membrane. A study suggests CoQ10 may reduce symp-
toms related to heart failure and increased energy pro-
duction in heart muscle [40]. Statins sometimes cause
muscle pain and oral CoQ10 might reduce this pain
[40,41].
In our study we observed that ATV decreased mito-
chondrial respiration but ATV and CoQ10 improved
mitochondrial function using succinate as substrate. Sta-
tins have been associated with a reduction in serum and
muscle tissue coenzyme Q10 levels that may play a role
in statin-induced myopathy. Aged people appear to be
more susceptible to coenzyme Q10 deficiency. Athletes
also require the most efficient oxygen consumption bymitochondria for their performance, and are more sus-
ceptible to CoQ10 deficiency. However, there is not a
general opinion regarding the effectiveness of CoQ10
supplementation. It seems that those that would gain
the major benefit from this supplementation are the hy-
percholesterolemic patients.
Conclusions
Our results support that the combination ATV and
CoQ10 improves biochemical parameters, liver mito-
chondrial respiratory function in hypercholesterolemic
rats with high ATV doses. These results have implica-
tions when considering statin safety and effectiveness.
Supplementation with CoQ10 may add beneficial effects
in hypercholesterolemic patients, being harmless for hu-
man beings and also having a hepato-protector action.
Methods
Chemical compounds
All chemicals were purchased from Sigma (St Louis, Mo,
USA): sucrose, HEPES (4 - (2-hydroxiethyl)-1-piperazine
ethane sulfonic acid, EGTA (ethylen glycol tetraacetic
acid), succinic acid, phosphoric acid, magnesium chlor-
ide, potassium chloride, bovine serum albumin, sodium
deoxycholate, cholesterol, adenosine 5'-diphosphate so-
dium salt (ADP), ethanol, coenzyme Q10, and Atorva-
statin (Lipitor) from Pfizer.
Animals and diets
Male Wistar rats were obtained from Unidad de Produc-
ción, Cuidado y Experimentación Animal (UPCEA), Div-
isión Académica de Ciencias de la Salud (DACS),
Universidad Juárez Autónoma de Tabasco (UJAT), verified
by the Secretaria de Agricultura, Ganadería y Recursos
Pecuarios (SAGARPA 2005). All procedures were subject
to regulations of animal experimentation from the Norma
Oficial Mexicana NOM-062-ZOO-1999, and the Inter-
national Guide for caring and use of laboratory animals
NRC 2002, with the approval of the Ethics Committee of
Faculty of Medicine, UNAM (PAPIIT-IN221914). Rats at
the age of 7 weeks and 180–200 g body weight were main-
tained under controlled housing conditions: 55% humid-
ity, 21 ± 1°C temperature, 12–12 h light–dark cycle. The
Harlan Laboratories diet (2018S) with 18.6% protein,
44.2% carbohydrates, 6.2% fat was used to prepare the di-
ets of each groups (n = 8 each one). The desing of this
study included two experiments:
Experiment 1: The total number of animals used was 48,
divided into 8 groups. No one had CoQ10 supplementation:
CD Control diet
CD + ATV2 (atorvastatin 0.56 mg/day)
HD Hypercholesterolemic diet (2% cholesterol, 0.6%
sodium deoxycholate).
HD + ATV1 (atorvastatin 0.2 mg/day)
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Experiment 2: The total number of animals used was
48, divided into 8 groups. All groups received CoQ10
0.57 mg/day as supplement:
CD Control diet
CD + ATV2 (atorvastatin 0.56 mg/day)
HD Hypercholesterolemic diet (2% cholesterol, 0.6%
sodium deoxycholate).
HD + ATV1 (atorvastatin 0.2 mg/day)
HD +ATV2 (atorvastatin 0.56 mg/day)
HD +ATV3 (atorvastatin 1.42 mg/day)
All Animals were given free access to water and diets
during the six week experimental time. Diets were
freshly prepared each day with grinded food. Body
weight was assessed once a week. All animals were kept
under the above mentioned experimental conditions for
a 6-week period. At the end of treatment and after a
12 h food withdrawal, rats were sacrificed by decapita-
tion. The liver was removed, weighted and 0.5 g were
used for biochemical determinations, the remaining liver
tissue was used for the assay of mitochondrial respira-
tory function.
Biochemical parameters
Blood was collected and serum was immediately frozen
and stored at −70°C until the biochemical determinations
were performed. Serum levels of glucose, cholesterol, tri-
acylglycerols, high-density lipoprotein-cholesterol (HDL-C),
aspartate aminotransferase (AST), and alanine aminotrans-
ferase (ALT) were analyzed using a Clinical Chemistry
System from Random Access Diagnostics.
Cholesterol and triacylglycerols from the liver
Liver lipids were extracted according to the Folch et al.
[42] (1957) procedure, whereas triacylglycerols and chol-
esterol concentrations were measured using enzymatic
colorimetric determinations according to diagnostic kits
from BioSystems Laboratories.
Mitochondria isolation
Hepatic mitochondria were harvested by centrifugation,
washed twice with 250 mM sucrose, 0.5 mM HEPES,
0.5 mM EGTA (SHE) buffer and resuspended in SHE
pH 7.2 at a final ratio of 5 ml/g wet weight. Subsequent
steps were carried out in the same buffer at 4°C and
mitochondria were isolated by differential centrifugation.
Briefly, cell debris was eliminated by centrifugation at
3000 g for 10 min, the mitochondrial pellet was obtained
by spinning the supernatant for 10 min at 12000 g, it
was washed once to eliminate cytosolic contamination,
and suspended with SHE buffer to a final protein con-
centration of 10–30 mg/mL. Protein determination was
performed using the Bradford method [43] (1976).Oxygen consumption
Respiratory measurements were carried out in 3.5 ml of
air-saturated medium with 5 mM succinate, 2 mM
MgCl2, 2 mM H3PO4, 2 mM EGTA, 30 mM HEPES,
0.1% BSA, pH 7.2 at 24°C. Oxygen consumption was de-
termined using a Clark-type oxygen electrode. Data are
expressed as the respiratory control ratio (RCR), which
is a relative value of state 3 and state 4 that indicates the
respiratory coupling in availability of ADP [44] (1967).
Statistical analysis
Comparisons between means were performed using
One-way analysis of variance (ANOVA), followed by
Student–Newman–Keuls test and differences between
the groups were determined by the Student's t test
(without CoQ10 vs with CoQ10). Differences were con-
sidered to reach statistical significance when p < 0.05.
For the post hot calculation of the statistical power in
the ANOVA test for the experiment, we used the
G*Power 3.0.10 software (Franz Faul, Universität Kiel,
Germany). We used 20% difference in group (i.e. effect
size), α level of 0.05, Total sample size: 96 and number
of groups 8, and the value of 16 animals needed, then
the power was of 1.00.
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